Massachusetts General Hospital, Boston, MA.
American Society of Clinical Oncology, Alexandria, VA.
J Clin Oncol. 2020 May 20;38(15):1736-1743. doi: 10.1200/JCO.19.03148. Epub 2020 Jan 28.
In 2017, Cancer Care Ontario's Program in Evidence-Based Care released the Bone Health and Bone-Targeted Therapies for Prostate Cancer guideline. This guideline included recommendations across a relatively broad clinical spectrum within prostate cancer. Topics addressed ranged from management of osteoporotic fracture risk in nonmetastatic disease to management of men with castration-resistant prostate cancer metastatic to bone. ASCO has a policy and set of procedures for endorsing clinical practice guidelines that have been developed by other professional organizations.
The Bone Health and Bone-Targeted Therapies for Prostate Cancer guideline was reviewed for developmental rigor by methodologists. An ASCO Expert Panel then reviewed the content and the recommendations.
The ASCO Expert Panel determined that the recommendations from the Bone Health and Bone-Targeted Therapies for Prostate Cancer guideline were clear, thorough, and based on the most relevant scientific evidence. ASCO wholly endorses the Bone Health and Bone-Targeted Therapies for Prostate Cancer guideline.
The ASCO Expert Panel endorses all the original guideline recommendations as written and offers a series of discussion points to guide practice for clinicians as they manage bone-related risks within this patient population.
2017 年，安大略省癌症护理计划发布了《前列腺癌的骨骼健康和骨靶向治疗指南》。本指南涵盖了前列腺癌中相对广泛的临床领域的建议。涉及的主题从非转移性疾病中骨质疏松性骨折风险的管理到去势抵抗性前列腺癌骨转移患者的管理。ASCO 有一项政策和一套程序，用于认可其他专业组织制定的临床实践指南。
方法学家对骨骼健康和前列腺癌骨靶向治疗指南的发展严谨性进行了审查。然后，ASCO 专家小组审查了内容和建议。
ASCO 专家小组确定，《前列腺癌的骨骼健康和骨靶向治疗指南》中的建议明确、全面，并基于最相关的科学证据。ASCO 完全认可《前列腺癌的骨骼健康和骨靶向治疗指南》。
ASCO 专家小组认可所有原始指南建议，并提供了一系列讨论要点，以指导临床医生在管理该患者人群中的骨骼相关风险时的实践。
